149 related articles for article (PubMed ID: 36724434)
1. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
Jacobs TG; Mumbiro V; Chitsamatanga M; Namuziya N; Passanduca A; Domínguez-Rodríguez S; Tagarro A; Nathoo KJ; Nduna B; Ballesteros A; Madrid L; Mujuru HA; Chabala C; Buck WC; Rojo P; Burger DM; Moraleda C; Colbers A; ;
J Acquir Immune Defic Syndr; 2023 May; 93(1):42-46. PubMed ID: 36724434
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
[TBL] [Abstract][Full Text] [Related]
3. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
Boulanger C; Rolla V; Al-Shaer MH; Peloquin C
Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214
[TBL] [Abstract][Full Text] [Related]
5. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
[TBL] [Abstract][Full Text] [Related]
6. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
[TBL] [Abstract][Full Text] [Related]
7. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.
Chaivichacharn P; Avihingsanon A; Gatechompol S; Ubolyam S; Punyawudho B
Drug Metab Pharmacokinet; 2022 Dec; 47():100478. PubMed ID: 36375225
[TBL] [Abstract][Full Text] [Related]
8. Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda.
Mulindwa F; Castelnuovo B; Kirenga B; Kalibbala D; Haguma P; Muddu M; Semitala FC
BMC Infect Dis; 2021 Aug; 21(1):822. PubMed ID: 34399706
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
[TBL] [Abstract][Full Text] [Related]
10. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895016
[TBL] [Abstract][Full Text] [Related]
11. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
Decloedt EH; McIlleron H; Smith P; Merry C; Orrell C; Maartens G
Antimicrob Agents Chemother; 2011 Jul; 55(7):3195-200. PubMed ID: 21537021
[TBL] [Abstract][Full Text] [Related]
13. Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.
Chabala C; Turkova A; Kapasa M; LeBeau K; Tembo CH; Zimba K; Weisner L; Zyambo K; Choo L; Chungu C; Lungu J; Mulenga V; Crook A; Gibb D; McIlleron H;
Pediatr Infect Dis J; 2023 Oct; 42(10):899-904. PubMed ID: 37506295
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
15. Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
Sunpath H; Winternheimer P; Cohen S; Tennant I; Chelin N; Gandhi RT; Murphy RA
Int J Tuberc Lung Dis; 2014 Jun; 18(6):689-93. PubMed ID: 24903940
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
17. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe.
Pasipanodya B; Kuwengwa R; Prust ML; Stewart B; Chakanyuka C; Murimwa T; Brophy J; Salami O; Mushavi A; Apollo T
J Int AIDS Soc; 2018 Dec; 21(12):e25214. PubMed ID: 30549217
[TBL] [Abstract][Full Text] [Related]
18. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
[TBL] [Abstract][Full Text] [Related]
19. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
20. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
